Pharmafile Logo

Zelboraf

- PMLiVE

Regeneron’s Libtayo approved as flexible dosing schedule in EU

The flexible dosing schedule has been approved for patients with skin, lung and cervical cancer

- PMLiVE

Roche’s Gazyva/Gazyvaro approved by FDA for primary membranous nephropathy

This rare, chronic autoimmune disease can cause kidney failure if left untreated

- PMLiVE

Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

- PMLiVE

Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

- PMLiVE

Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn

The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases

- PMLiVE

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

The results from a global phase 3 trial show the longest survival data ever reported in this setting

- PMLiVE

Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

- PMLiVE

Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment

This is the first and only at-home subcutaneous treatment option for this disease

- PMLiVE

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

- PMLiVE

Roche and Nurix Therapeutics to partner in $2.3bn deal

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

- PMLiVE

Roche opens new Swiss Institute of Human Biology research facility

The new building is part of a 1.5bn euro site investment

- PMLiVE

Roche’s Columvi improves survival in large B-cell lymphoma

Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links